Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells

Clinical and Experimental Immunology

Volumn 130, Issue 1, 2002, Pages 85-92

  Kalthoff, Frank S ^a   Chung, J ^a   Stuetz, A ^a  

^a NOVARTIS RESEARCH INSTITUTE   (Austria)

Author keywords

Allogeneic MLC cytokines dendritic cells OX 40 T cells

Indexed keywords

ALLOANTIGEN; CD134 ANTIGEN; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; PIMECROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; CELL SURVIVAL; CHRONIC INFLAMMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; DRUG POTENCY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURIFICATION; REGULATORY MECHANISM; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD27; CELLS, CULTURED; CYCLOSPORINE; CYTOKINES; DENDRITIC CELLS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; ISOANTIGENS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MOLECULAR STRUCTURE; RECEPTORS, INTERLEUKIN-2; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; TACROLIMUS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0036379802     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01962.x     Document Type: Article

References (31)

1. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a co-stimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991; 147:2461-6.
2. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994; 15:321-31.
3. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Ann Rev Immunol 1993; 11:191-212.
4. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, co-stimulation, and death. Cell 1994; 76:959-62.
5. Latza U, Dürkop H, Schnittger S et al. The human OX40 homolog. cDNA structure, expression and chromosomal assignment of the ACT35 antigen. Eur J Immunol 1994; 24:677-83.
6. Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G. Expression and function of OX40 ligand on human dendritic cells. J Immunol 1997; 159:3838-48.
7. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001; 15:445-55.
8. Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M. The OX40 co-stimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 2000; 165:3043-50.
9. Maxwell JR, Weinberg AD, Prell RA, Vella AT. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol 2000; 164:107-12.
10. Higgins LM, McDonald SAC, Whittle N, Crockett N, Shields JG, MacDonald TT. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40-ligand-IgG fusion protein. J Immunol 1999; 162:486-93.
11. Weinberg AD, Wegmann KW, Funatake C, Whitham R. Blocking OX40/OX40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol 1999; 162:1818-26.
12. Yoshioka T, Nakajima A, Akiba H et al. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol 2000; 30:2815-23.
13. Chen AI, McAdam AJ, Buhlmann JE et al. OX40-ligand has a critical co-stimulatory role in dendritic cell: T cell interactions. Immunity 1999; 11:689-98.
14. Murata K, Ishii N, Takano H et al. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J Exp Med 2000; 191:365-74.
15. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin Cutaneous Med Surg 2001; 20:233-41.
16. Paul C, Graeber M, Stuetz A. Ascomycins. promising agents for the treatment of inflammatory skin diseases. Expert Opin Invest Drugs 2000; 9:69-77.
17. Hebert A. WarkenKA, Cherill R. Pimecrolimus cream 1%. A new development in non-steroid topical treatment of inflammatory skin diseases. Seminars Cutaneous Med Surg 2001; 20:260-7.
18. Grassberger M, Baumruker T, Enz A et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141:264-73.
19. Roos AEJM, Schilder-Tol Weening JJ, Aten J. Strong expression of CD134 (OX40), a member of the TNF receptor family, in a T helper 2-type cytokine environment. J Leukoc Biol 1998; 64:503-10.
20. Juedes AE, Hjelmström P, Bergman CM, Neild AL, Ruddle NH. Kinetics and cellular origin of cytokines in the central nervous system: insight into mechanisms of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. J Immunol 2000; 164:419-26.
21. Mallett S, Fossum S, Barclay AN. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes - a molecule related to nerve growth factor receptor. EMBO J 1990; 9:1063-8.
22. Calderhead DM, Buhlmann JE, van den Eertwegh AJM, Claassen E, Noelle RJ, Fell HP. Cloning of mouse OX40: a T cell activation marker that may mediate T-B cell interactions. J Immunol 1993; 151:5261-71.
23. Matsumura Y, Imura A, Hori T, Uchiyama T, Imamura S. Localization of OX40/gp34 in inflammatory skin diseases: a clue to elucidate the interaction between activated T cells and endothelial cells in infiltration. Arch Dermatol Res 1997; 289:653-6.
24. Tsukada N, Akiba H, Aizawa Y, Yagita H, Okumura K. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood 2000; 95:2434-9.
25. Malmstrom V, Shipton D, Singh B Al-et al. CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. J Immunol 2001; 166:6972-81.
26. Ndhlovu LC, Ishii N, Murata K, Sato T, Sugamura K. Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis. J Immunol 2001; 167:2991-9.
27. Nohara C, Akiba H, Nakajima A et al. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells. J Immunol 2001; 166:2108-15.
28. Giacomelli R, Passacantando A, Perricone R et al. T lymphocytes in the synovial fluid of patients with active rheumatoid arthritis display CD134-OX40 surface antigen. Clin Exp Rheumatol 2001; 19:317-20.
29. Weinberg AD, Wallin JJ, Jones RE et al. Target organ-specific up-regulation of the MRC OX40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelitis. Immunol 1994; 152:4712-21.
30. Weinberg AD, Sullivan TJ, Lemon M et al. Selective depletion of myelin-reactive T cells with the anti-OX40 antibody ameliorates autoimmune encephalomyelitis. Nat Med 1996; 2:183-9.
31. Bansal-Pakala P, Jember A, Croft M. Signaling through OX40 (CD134) breaks peripheral T cell tolerance. Nat Med 2001; 7:907-12.